Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2004;8(4):129-33.
doi: 10.1080/13577140400016705.

A Phase II Study of Docetaxel and Epirubicin in Advanced Adult Soft Tissue Sarcomas (STS)

Haralabos P Kalofonos  1 , Charalabos Kourousis, Michalis V Karamouzis, Gregoris Iconomou, Ekaterini Tsiata, Fotis Tzorzidis, Panagiotis Megas, Elias Lambiris, Vasilios Georgoulias
Affiliations

A Phase II Study of Docetaxel and Epirubicin in Advanced Adult Soft Tissue Sarcomas (STS)

Haralabos P Kalofonos et al. Sarcoma. 2004.

Abstract

Purpose: The aim of this study was to determine the efficacy and safety of docetaxel plus epirubicin combination as first-line chemotherapy in patients with locally advanced and/or metastatic adult STS.

Patients and methods: Eighteen patients were treated with epirubicin 30 mg/m(2) on days 1 to 3 and docetaxel 100 mg/m(2) on day 1 every 3 weeks.

Results: Fifteen out of 18 patients (83.4%) were assessable for response. No complete response was recorded. Three (20%) patients achieved PR, 3 had SD and 9 PD. The overall median survival was 14 months (range, 3-48 months) and the median time to disease progression was 4 months (range, 2-45 months). Grade >/= 3 neutropenia occurred in 88% and neutropenic fever in 27.8% of patients. Other toxicities were mild. No treatment related deaths occurred.

Discussion: Docetaxel plus epirubicin combination achieved low response rate with severe myelotoxicity in patients with advanced STS.

PubMed Disclaimer

References

    1. Clin Cancer Res. 2000 Apr;6(4):1255-8 - PubMed
    1. Expert Rev Anticancer Ther. 2003 Apr;3(2):179-84 - PubMed
    1. Am J Clin Oncol. 2004 Jun;27(3):307-11 - PubMed
    1. J Clin Oncol. 1989 Sep;7(9):1208-16 - PubMed
    1. Cancer Treat Rev. 1993 Jul;19(3):197-228 - PubMed